Your search returned 2 results.

Results
	1.	Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. [electronic resource] by Zaman, Khalil Winterhalder, Ralph Mamot, Christoph Hasler-Strub, Ursula Rochlitz, Christoph Mueller, Andreas Berset, Catherine Wiliders, Hans Perey, Lucien Rudolf, Christine Biaggi Hawle, Hanne Rondeau, Stephanie Neven, Patrick Producer: 20150901 In: European journal of cancer (Oxford, England : 1990) vol. 51 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. [electronic resource] by Rochlitz, Christoph Bigler, Martin von Moos, Roger Bernhard, Jürg Matter-Walstra, Klazien Wicki, Andreas Zaman, Khalil Anchisi, Sandro Küng, Marc Na, Kyung-Jae Bärtschi, Daniela Borner, Markus Rordorf, Tamara Rauch, Daniel Müller, Andreas Ruhstaller, Thomas Vetter, Marcus Trojan, Andreas Hasler-Strub, Ursula Cathomas, Richard Winterhalder, Ralph Producer: 20170926 In: BMC cancer vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)